Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 27;17:3033–3044. doi: 10.2147/CCID.S498987

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 Maxwell et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Tyrosinase enzyme activity in HEMn cells was evaluated by measuring formation of dopachrome (a melanin precursor) in a 3-point dose response after 14 days in culture. Cells were treated with RXI-231 on days 1 and 7 and had media replenishment twice weekly. RXI-231 showed a dose-dependent reduction of dopachrome with only 2 weekly doses of compound (A). Primary human melanocytes were also evaluated for melanin content following the 14 day transfection. Treatment with RXI-231 resulted in a 40% reduction in melanin content (B). ****p<0.0001, ***p<0.001.